Outlook Therapeutics (OTLK) versus Vericel (VCEL) Head to Head Comparison
Outlook Therapeutics (NASDAQ:OTLK) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.
This table compares Outlook Therapeutics and Vericel’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Outlook Therapeutics and Vericel’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Outlook Therapeutics||$3.09 million||5.91||-$30.09 million||N/A||N/A|
|Vericel||$90.86 million||8.92||-$8.14 million||($0.14)||-132.14|
Vericel has higher revenue and earnings than Outlook Therapeutics.
Volatility and Risk
Outlook Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.02, suggesting that its stock price is 202% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Outlook Therapeutics and Vericel, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vericel has a consensus price target of $20.31, suggesting a potential upside of 9.77%. Given Vericel’s higher probable upside, analysts plainly believe Vericel is more favorable than Outlook Therapeutics.
Institutional and Insider Ownership
4.6% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 83.3% of Vericel shares are held by institutional investors. 11.5% of Outlook Therapeutics shares are held by insiders. Comparatively, 4.5% of Vericel shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vericel beats Outlook Therapeutics on 9 of the 11 factors compared between the two stocks.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.